KMKuansheng Ma

Kuansheng Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kuansheng Ma has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive Value of Age-Adjusted Charlson Comorbidity Index on Survival Outcomes of Hepatocellular Carcinoma Patients with Comorbidities Undergoing Radiofrequency Ablation

    by Yuzheng Yan, Sijie Xiao, Feng Xia, Huaqiang Bi, Chunlin Tang, Kai Feng, Kuansheng Ma, Qiang Wang

    This study aimed to explore the predictive value of Age-Adjusted Charlson Comorbidity Index (ACCI) on survival outcomes in patients with hepatocellular carcinoma (HCC) and comorbidities undergoing radiofrequency ablation (RFA). This study is a retrospective, single-center study which included 158 patients with HCC newly diagnosed at our center from January 2015 to December 2021 who had comorbidities prior to RFA treatment. Patients were divided into two groups (≤4 and >4) according to the optimal cutoff value of ACCI determined by X-tile analysis based on overall survival (OS), and comprehensive clinical, laboratory, and tumor characteristic data were collected. The primary endpoints were OS and recurrence-free survival (RFS), analyzed using the Kaplan-Meier method and Cox proportional hazards model. Patients in the high ACCI group (>4) were independently associated with worse OS and RFS compared to those in the low ACCI group (≤4). Multivariate Cox analysis confirmed that ACCI >4 was an independent risk factor for both OS and RFS, with hazard ratios (HR) of 2.07 and 2.05, respectively. In addition to ACCI, other independent predictors for worse OS included tumor max-diameter (HR: 1.69, P < 0.001) and elevated level of preoperative α-fetoprotein (HR: 1.91, P = 0.007), while preoperative albumin (HR: 0.93, P=0.001) was a significant protective factor for OS. For RFS, significant risk factors included tumor max-diameter (HR: 1.79, P < 0.001) and prothrombin time ≥ 13 seconds (HR: 2.38, P = 0.001). ACCI may serve as a useful prognostic predictor for survival outcomes in HCC patients with comorbidities undergoing RFA.

  • Open Access

    Long-Term Outcome of No-Touch Radiofrequency Ablation for Treating AFP-Positive Small Hepatocellular Carcinoma

    by Guodong Wu, Xianqi Huang, Xia Ou, Mengda Zou, Feng Xia, Leida Zhang, Kai Feng, Kuansheng Ma, Qiang Wang

    This study aimed to evaluate the short- and long-term efficacy of no-touch radiofrequency ablation (NT-RFA) in treating patients with AFP-positive, solitary hepatocellular carcinoma (HCC) with a diameter of ≤ 3cm, and to assess its effect on AFP levels. A retrospective analysis was conducted on 245 AFP-positive HCC patients treated with NT-RFA (n=78) and Conventional RFA (C-RFA) (n=167) at our center between 2015 and 2023. The changes of AFP levels were compared. Statistical analysis was conducted on the overall survival(OS), recurrence free survival(RFS), and tumor recurrence status of the two groups at 1 to 5-years post-RFA. The decrease in postoperative AFP levels was significantly greater in the NT-RFA group than that in the C-RFA group (P=0.009), and the postoperative AFP seronegative rate in the NT-RFA group was significantly higher than that in the C-RFA group (P=0.020). The OS rates at 1-, 3-, and 5-years were 100.00%, 71.07%, and 54.07% for NT-RFA group, while 95.21%, 62.06%, and 30.80% for C-RFA group. Significant differences existed between the two groups (P=0.026). The 1-, 3-, and 5-year RFS rates in the NT-RFA group were 79.49%, 46.36%, and 29.96%, while 65.87%, 30.99%, and 21.20% in the C-RFA group. Significant differences existed between the two groups (P=0.025). The 1-, 3-, and 5-year local tumor progression-free survival (LTP-FS) rates were 89.67%, 83.31%, 81.06% in the NT-RFA group and 79.01%, 64.61%, 63.10% in the C-RFA group. Significant differences existed between the two groups (P=0.002). But there was no significant difference in intrahepatic distant recurrence-free survival (IDR-FS) between the two groups (P=0.819). Compared with C-RFA, NT-RFA treatment for AFP positive HCC ≤ 3cm is more effective in reducing postoperative AFP levels and improving the rate of AFP conversion to negative. Meanwhile, NT-RFA significantly increased RFS and OS. It can replace C-RFA as the primary treatment method for AFP-positive small HCC.

  • Open Access

    No-touch versus conventional radiofrequency ablation for treating solitary recurrent hepatocellular carcinoma ≤ 3 cm: a retrospective cohort study

    by Guodong Wu, Xia Ou, Mengda Zou, Feng Xia, Leida Zhang, Kai Feng, Kuansheng Ma, Qiang Wang

    Objective This study aimed to compare the outcomes of no-touch radiofrequency ablation (NT-RFA) and conventional RFA (C-RFA) in the treatment of solitary recurrent hepatocellular carcinoma (rHCC) ≤ 3 cm. Methods 255 patients with rHCC treated with RFA in our center from January 2017 to December 2023 were retrospectively analyzed (NT-RFA: 63, C-RFA: 192 patients). Short- and long-term outcomes were compared, and survival rates were calculated. Results The ablation range and safety margin differed significantly between the two groups (both p < 0.01). The 1-, 3-, and 5- years overall survival (OS) rates were 96.83%, 75.51% and 45.61% respectively in the NT-RFA group, while 97.39%, 77.48% and 48.56% in the C-RFA group, with no significant difference between the two groups (P = 0.510). The 1-, 3-, and 5-year recurrence-free survival (RFS) rates in the NT-RFA group were 73.02%, 46.22% and 36.77%, respectively, while 69.70%, 38.95% and 27.78% in the C-RFA group, with no significant difference between the two groups (P = 0.338). The 1-, 3-, 5-year local tumor progression (LTP) free survival rates in the NT-RFA and C-RFA group were 84.13%, 67.04%, 67.04% and 78.02%, 53.70%, 48.80% respectively, with significant difference between the two groups (P = 0.047). However, there was no significant difference in intrahepatic distant recurrence free survival rates between the two groups (P = 0.068). Conclusion NT-RFA treatment for rHCC ≤ 3 cm is as safe as C-RFA, but it achieves a larger ablation range and safety margin. Although NT-RFA does not significantly improve RFS or OS in rHCC ≤ 3 cm, it significantly reduces the LTP.

  • Open Access

    Subsegmental radiofrequency ablation: a novel ablation technique based on portal territory for treatment of hepatocellular carcinoma

    by Sijie Xiao, Yuzheng Yan, Chunlin Tang, Changfeng Li, Qiang Wang, Huaqiang Bi, Kuansheng Ma

    To propose a novel ablation technique based on portal territory (PT) namely subsegmental radiofrequency ablation (SS-RFA) and evaluate its safety, feasibility and effectiveness. This study prospectively included 17 patients with single HCC ≤ 50 mm who underwent SS-RFA at a tertiary medical center between October 2022 and April 2024. Before SS-RFA, 3D reconstruction and watershed analysis based on preoperative contrast-enhanced CT was first performed to find out which subsegment contain tumor, and the corresponding subsegmental Glisson pedicle to be ablated was selected. Then ablation of selected Glisson pedicle and tumor was performed successively. The safety, efficacy and feasibility of SS-RFA were evaluated. SS-RFA was performed on 17 tumor lesions (mean diameter 23.41 mm ± 8.80) and the corresponding subsegmental Glisson pedicles in 17 HCC participants (mean age 57.35 ± 10.54 years; 14 males, 3 females). Postoperative contrast-enhanced ultrasound showed an increased mean diameter of the ablation zone 48 h after SS-RFA compared with 15-30 min after SS-RFA (54.85 mm ± 2.47 vs 47.85 mm ± 1.78, p<.05). Three-dimensional reconstruction based on contrast-enhanced CT 2-3 days after ablation showed lack of enhancement of the ablated Glisson pedicle and its corresponding subsegment, with an average conical necrosis volume of 50.70 ± 25.31 cm3. No major complications occurred. During a median follow-up of 9.2 months (2.6-23.4), no participant died, and no local tumor progression was observed. SS-RFA based on PT is a safe, technically feasible procedure in the treatment of patients with solitary HCC ≤ 50 mm.

  • Laparoscopic liver resection versus radiofrequency ablation for small hepatocellular carcinoma: randomized clinical trial

    by Juxian Song, Li Cao, Kuansheng Ma, Jianwei Li, Xiaojun Wang, Jian Chen, Shuguo Zheng

    Background: The aim of this study was to compare the efficacy of laparoscopic liver resection versus radiofrequency ablation for treatment of small hepatocellular carcinoma. Methods: This single-centre RCT was conducted at a tertiary referral centre in China. Patients with small hepatocellular carcinoma who had a single nodule no larger than 5 cm, or up to three nodules of 3 cm or smaller, were eligible. Patients were assigned randomly in a 1 : 1 ratio to either laparoscopic liver resection or radiofrequency ablation. Blinding was not attempted. Sample size calculations led to 75 patients per group. The primary outcome was overall survival, and the secondary outcome was recurrence-free survival. Results: Seventy-five patients were included in each group. Overall survival (HR 1.26, 95% c.i. 0.69 to 2.30; P = 0.451) and recurrence-free survival (HR 1.34, 0.86 to 2.08; P = 0.189) did not differ between the resection and ablation groups. The 1-, 3- and 5-year overall survival rates were 94.7, 80.0, and 74.7% respectively after laparoscopic liver resection versus 93.3, 78.7, and 67.9% after radiofrequency ablation. Corresponding recurrence-free survival rates were 78.7, 61.3, and 51.6%, and 69.3, 53.3, and 41.0%, respectively. Conclusion: For small hepatocellular carcinoma, percutaneous radiofrequency ablation provides therapeutic effects similar to those of laparoscopic liver resection. Registration number: NCT02243384 (http://www.clinicaltrials.gov).


  • Open Access

    Long‐term efficacy of no‐touch radiofrequency ablation in the treatment of single small hepatocellular carcinoma: A single center long‐term follow‐up study

    by Guodong Wu, Jing Li, Changfeng Li, Xia Ou, Kai Feng, Feng Xia, Zhiyu Chen, Leida Zhang, Kuansheng Ma

    ObjectiveTo evaluate the long-term efficacy of no-touch radiofrequency ablation (NT-RFA) for treating single hepatocellular carcinoma (HCC) less than 3 cm. MethodsA total of 331 patients with HCC less than 3 cm undergoing RFA in Southwest Hospital from 2015 to 2020 were analyzed retrospectively. All patients were divided into NT-RFA group (n = 113) and conventional RFA (C-RFA) group (n = 218). The survival rate, local tumor progression (LTP) and intrahepatic distant recurrence (IDR) of the two groups were calculated and compared. ResultsA significant difference was observed in ablation range (p = 0.000) and safety margin (p = 0.000) between the two groups. The 1-, 2-, 3-, 4-and 5-year overall survival (OS) rates in NT-RFA and C-RFA group were 99.12%, 93.73%, 76.18%, 57.00%, 45.17% and 99.08%, 89.91%, 71.26%, 54.28%, 41.77%, respectively. There was no significant difference between the two groups (p = 0.281). The 1-, 2-, 3-, 4-and 5-year recurrence-free survival (RFS) rates in NT-RFA and C-RFA group were 78.51%, 52.59%, 41.02%, 34.36%, 30.92% and 68.81%, 44.95%, 30.88%, 23.73%, 22.88%, respectively. The two groups differed significantly (p = 0.044). The 1-, 3-and 5-year LTP-free survival rates in NT-RFA and C-RFA group were 87.12%, 74.99%, 72.32% and 75.75%, 65.52%, 65.52%, respectively. The two groups also differed significantly (p = 0.024). Furthermore, the RFS rates of D <= 2 cm subgroups in NT-RFA and C-RFA groups differed significantly (p = 0.037), while the RFS rates of 2 cm < D <= 3 cm subgroups in two groups showed no significant difference (p = 0.578). ConclusionsThe RFS rates of single HCC less than 3 cm treated by NT-RFA was significantly higher than that of C-RFA. Due to a larger ablation range and safety margin, NT-RFA could significantly reduce LTP and improve RFS. Dual-electrode NT-RFA can significantly improve the RFS rate of patients with HCC less than 2 cm, but there is no obvious advantage compared with C-RFA in the treatment of HCC over 2 cm.


  • Open Access

    Radiofrequency ablation in the treatment of hepatocellular carcinoma

    by Qingsong Deng, Minglian He, Chunchuan Fu, Kai Feng, Kuansheng Ma, Leida Zhang

    The purpose of this article is to discuss the use, comparative efficacy, and research progress of radiofrequency ablation (RFA), alone or in combination with other therapies, for the treatment of h...


  • The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B

    by Dan Yang, Hong Hu, Rui Li, Chun-Lin Tang, Kuan-Sheng Ma, De-Yu Guo

    Purpose To explore the diagnostic value of American College of Radiology Contrast-Enhanced Ultrasound-Liver Imaging Reporting and Data System (ACR-CEUS-LI-RADS) for hepatocellular carcinoma (HCC) in patients with cirrhosis and chronic hepatitis B. Methods A total of 205 patients at high risk of HCC with solitary hepatic nodule were enrolled and retrospectively analyzed. All patients were over 18 years old and had a single lesion with a diameter < 50 mm. Lesions were categorized according to size and contrast enhancement patterns in the arterial, portal venous and late phases. Diagnostic efficacy of CEUS LI-RADS for HCC, and the rate of non-HCC malignancies in the LR-M class were compared between patients with cirrhosis and chronic hepatitis B. Results Of all 205 nodules (median nodule size was 34 mm), 142 (69.3%) were HCC. Of the 127 (61.9%) LR-5 category nodules, 95.8% (92/96) nodules were corresponded to HCC in cirrhosis, while 61.3% (19/31) nodules were corresponded to HCC in chronic hepatitis B (P = 0.000). Positive predictive value (PPV) of LR-5 category for HCC was 95.8% in cirrhosis and 61.3% in chronic hepatitis B (P = 0.000). More category of LR-4 nodules were proved to be HCC in patients with cirrhosis than chronic hepatitis B (80.0% vs 8.3%, P = 0.000). Of 41 LR-M category nodules, more non-HCC malignancies were found in chronic hepatitis B (76.0%) than that in cirrhosis (25.0%, P = 0.001). Conclusions The LR-5 category is highly specific for the diagnosis of HCC in patients with cirrhosis. However, LR-5 category nodules require further CT or MRI examination or histological confirmation in patients with chronic hepatitis B for its unsatisfactory PPV for HCC.